Allakos Inc.: Business Overview, Financials & Competitive Analysis
Allakos Inc. scores 3/10 on the AskCyborg Cyborg Score (Weak). Late-stage clinical-stage biotech with acquired pipeline assets now operated under Concentra Biosciences parent company; limited commercial traction and execution risk. Allakos was acquired at a significant discount ($0.33/share) in May 2025, indicating shareholder value destruction and difficulty progressing clinical-stage antibody programs to commercialization. The company faced biotech sector headwinds and.
What is Allakos Inc.'s industry? Allakos Inc. (allakos.com) operates in Monoclonal Antibodies. AskCyborg classifies Allakos Inc. under Monoclonal Antibodies in its company registry.
Allakos is a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases. The company was a...
Cyborg Score thesis
Late-stage clinical-stage biotech with acquired pipeline assets now operated under Concentra Biosciences parent company; limited...
Read the full analyst-debate transcript →Get the Latest Allakos Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAllakos Inc. Overview
Pro stress-test →Allakos is a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases. The company was acquired on May 15, 2025 by Concentra Biosciences following a strategic consolidation in the immunomodulatory therapeutics sector.
Strategic Profile
Pro stress-test →Allakos' primary product candidate is Antolimab (AK002), an investigational monoclonal antibody that selectively targets Siglec-8, a receptor found on mast cells and eosinophils, which play a key role in various allergic and inflammatory conditions. The company's R&D efforts are concentrated on conditions such as Eosinophilic Gastrointestinal Diseases (EGIDs), where Antolimab met all primary and secondary endpoints in a Phase 2 study, leading to the initiation of a Phase 3 study.
Competitive Landscape
Pro stress-test →Allakos competes with companies including Corvus Pharmaceuticals, Cogent Biosciences, Marker Therapeutics, Kite Pharma, and Coherus Oncology in the antibody therapeutics and immunomodulatory space, though most competitors target different receptor pathways or disease indications.
Industry Context
Allakos Inc. operates in Monoclonal Antibodies.
Key facts
Founded: 2012 · Headquarters: San Carlos, California, US · Employees: 61 · Market cap: $29.7M